VP

Vincent Piguet

Women's College Hospital, University of Toronto, Royal College of Physicians, General Medical Council, Cardiff University, Swiss Medical Association

Research areas: Medicine · Dermatology · Dermatology and Skin Diseases · Autoimmune and Inflammatory Disorders · Hidradenitis Suppurativa and Treatments

ORCID iD 0000-0001-6079-4517
Follow

About

Professor Vincent Piguet, MD, PhD, FRCP, trained at the School of Medicine, University of Geneva and graduated in 1995. He spent two years doing research in virology and immunology at the Salk Institute in San Diego, USA. He obtained his MD and PhD in 2000/2001 and his specialist certification in Dermatology & Venereology in 2004 from the Swiss Medical Association. He obtained a prestigious Fellowship from the Swiss National Science Foundation in 2003 and was subsequently promoted to Assistant and then Associate Professor at University of Geneva. In 2010 he was appointed Professor and Chair of the Department of Dermatology and Wound Healing at Cardiff University, Wales, UK and Honorary Consultant Dermatologist at the University Hospital of Wales. In 2011 he obtained UK certification in Dermatology and in 2014 became a Fellow of the Royal College of Physicians. In 2011 he was appointed Director of the Institute of Infection and Immunity, School of Medicine, Cardiff University and in 2015, Director of the Division of Infection and Immunity, School of Medicine, Cardiff University. In 2017, he was appointed as Full Professor and Department Division Director of Dermatology, Department of Medicine, University of Toronto and Division Head of Dermatology, Women’s College Hospital, Toronto.

Professor Piguet has authored over 260 publications in the fields of dermatology, dendritic cells, HIV, gene therapy, immunology and vaccination in a range of highly cited peer review journals such as Cell, Immunity, The Lancet, Proceedings of the National Academy of Sciences, Journal of Investigative Dermatology, Blood, and Nature Medicine. He has received numerous grants (including as principal investigator from the Human Frontier Science Program and the Bill & Melinda Gates Foundation) to further his research including in the areas of HIV, psoriasis, melanoma and immunology. He gave the 'Rudi Cormane Lecture' at the European Society for Dermatological Research (ESDR) in 2014 and has given more than 100 lectures at national and international meetings, including at the World Congress of Dermatology and HIV Keystone meetings. He received a merit award in 2014 from the Society for Arts, Science and Technology in Wales, The Welsh Livery Guild. He is on the editorial boards of several journals, including the Journal of Investigative Dermatology and British Journal of Dermatology. He is the Past-President of the ESDR and current Executive Board member, Treasurer and President-Elect of the European Dermatology Forum, a not for profit organization dedicated to improving the healthcare needs of dermatology patients in Europe. In 2017 was honoured with membership of the Academia Europaea, founded in 1988 to advance scholarship and education across all areas of science in Europe. As a member of the academy, Dr. Piguet joins the ranks of more than 70 Nobel Laureates and other prestigious scientists. Dr. Piguet was named a Fellow of the Canadian Academy of Health Sciences in 2021.

Employment

Education

  • Royal College of Physicians FRCP
    2014 - Present
  • General Medical Council Certified for entry on Specialist Register for Dermatology
    2011 - Present
  • Swiss Medical Association Specialist Certification in Dermatology & Venereology
    2004 - Present
  • Swiss Society of Dermatology & Venereology Specialist Degree in Dermatology & Venereology
    2002 - 2004
  • University of Geneva MD
    2001 - Present
  • University of Geneva Institute of Genetics and Genomics of Geneva PhD
    2000 - Present
  • Swiss Federal Department of Home Affairs Medical Degree
    1995 - Present

Projects & Funding

  • Immune response after COVID-19 vaccination during maintenance therapy in immunemediated inflammatory diseases: an observational cohort study (IMPACT) Juan and Stefania Speck (private donation)
    2021 - Present
  • Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 (vilobelimab) in treating subjects with Pyoderma Gangrenosum Innovaderm Research Inc
    2021 - 2022
  • Immune response after COVID-19 vaccination during maintenance therapy in immune-mediated inflammatory diseases: an observational cohort study (IMPACT) Canadian Institutes of Health Research
    2021 - 2022
  • Understanding IL-23-mediated inflammation in Plaque Psoriasis using Tissue Imaging Mass Cytometry (IMC) AbbVie Canada
    2021 - 2023
  • Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED) COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG)
    2021 - 2022
  • Canadian Atopic Dermatitis Cohort for Translational Immunology and Imaging (CACTI) Canadian Dermatology Foundation
    2020 - 2022
  • Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository - HS PROGRESS Women’s College Hospital Academic and Medical Services Group (WCHAMSG)
    2020 - 2023
  • Multidimensional Intervention Strategies to Prevent Onset of Psoriatic Arthritis National Psoriasis Foundation
    2020 - 2021
  • Tissue Imaging Mass Cytometry to Decipher Psoriasis Inflammation in Plaque and Paradoxical Psoriasis Canadian Dermatology Foundation
    2019 - 2022
  • Pyoderma Gangrenosum-associated disease activity and the intestinal microbiome Canadian Dermatology Foundation
    2019 - 2021
  • Skin Investigation Network of Canada (SkIN Canada) Canadian Institutes of Health Research
    2019 - 2022
  • Skin Immune Cells and Pathogens Facility (SPF) Ontario Ministry of Research, Innovation and Science
    2019 - 2020
  • Derivation and Validation of a Disease-Specific Cardiovascular Risk Prediction Score for Psoriatic Disease Using Patient Registry and Population-Based Data Canadian Institutes of Health Research
    2019 - 2020
  • Skin Immune Cells and Pathogens Facility (SPF) Canada Foundation for Innovation
    2017 - 2020
  • Cardiff Regional Experimental Arthritis Treatment and Evaluation Centre (CREATE) Arthritis Research UK, Health and Care Research Wales
    2015 - 2017
  • Defining pathogen sensing in human skin-derived dendritic cells Wellcome Trust
    2015 - 2019
  • Defining the Biological Functions of Novel Lipids in Healthy and Wounded Skin Medical Research Council
    2015 - 2020
  • Anti-viral activity of protide deriatives of human t-cells Welsh Government (HEFCW)
    2015 - 2016
  • Ipad Study Grant Janssen-Cilag Ltd
    2015 - 2016
  • Cardiovascular risk in patients with psoriatic rheumatoid arthritis Pfizer UK
    2015 - 2015
  • Systems Analysis of Dendritic Cells Interactions with HIV-1 during Cell-to-Cell Transmission: A focus on cytokine receptors URI
    2015 - 2019
  • Anti-viral activity of protide deriatives of human t-cells Welsh Government (HEFCW)
    2015 - 2015
  • Enhancing immune responses against chronic infection by targeting dermal and blood derived DC's with intradermally delivered vaccines Bill and Melinda Gates Foundation
    2011 - 2015
  • Autophagy as a cell-autonomous defense to eliminate HIV Bill and Melinda Gates Foundation
    2011 - Present
  • Infectious Synapse and Transmission of Disease Human Frontier Science Program
    2006 - 2009

Publications (325)